EGFR酪氨酸激酶抑制剂治疗相关毒性风险:吉非替尼、厄洛替尼和阿法替尼在晚期EGFR突变非小细胞肺癌临床试验中的荟萃分析
该荟萃分析纳入16项随机试验共2535例EGFR突变或野生型晚期NSCLC患者,比较吉非替尼、厄洛替尼和阿法替尼的毒性。结果显示吉非替尼G3/4不良事件风险较低(29.1%),阿法替尼皮疹和腹泻风险较高,肝酶升高风险以吉非替尼较高。
要点
- 毒性死亡罕见(1.7%),肺炎最常见,三种EGFR TKI间无显著差异。
- 吉非替尼G3/4不良事件风险(29.1%)低于厄洛替尼(54.1%)或阿法替尼(42.1%)(p < 0.01)。
- 阿法替尼皮疹(84.8%)和腹泻(91.7%)风险高于厄洛替尼或吉非替尼(p < 0.01)。
核心结论
- EGFR TKI耐受性良好,因不良事件停药率低于10%;不同EGFR TKI的毒性谱和风险存在差异,可用于指导治疗选择。
研究设计与样本
- 对比较EGFR TKI与化疗或安慰剂的随机试验进行荟萃分析,从EGFR TKI组提取数据进行间接比较,共纳入16项试验2535例EGFR突变或野生型患者。
主要发现
- 毒性死亡罕见(1.7%),肺炎最常见,EGFR TKI间无显著差异;40%患者发生G3/4不良事件。
- G3/4不良事件风险:吉非替尼29.1% vs 厄洛替尼54.1% vs 阿法替尼42.1%(p < 0.01),吉非替尼较低。
- 因不良事件停药发生于7.7%患者,EGFR TKI间无显著差异;腹泻(53.3%)和皮疹(66.5%)最常见。
- 皮疹风险:阿法替尼84.8% vs 厄洛替尼62.0% vs 吉非替尼62.0%(p < 0.01),阿法替尼较高。
- 腹泻风险:阿法替尼91.7% vs 厄洛替尼42.4% vs 吉非替尼44.4%(p < 0.01),阿法替尼较高;肝酶升高风险:吉非替尼61.7% vs 厄洛替尼17.8% vs 阿法替尼20.1%(p < 0.01),吉非替尼较高。
关键数值与推荐
- 采用风险-获益轮廓评估不同EGFR TKI疗效与毒性之间的权衡。
临床怎么用
- 不同EGFR TKI的毒性谱和风险存在差异,可用于指导治疗选择。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Gefitinib, erlotinib, and afatinib are tyrosine kinase inhibitors (TKIs) used for treatment of advanced EGFR-mutated NSCLC. Estimating differences in toxicity between these EGFR TKIs is important for personalizing treatment. METHODS: We performed a meta-analysis of randomized trials that compared EGFR TKI therapy against chemotherapy or placebo. We extracted data from the EGFR TKI arm for indirect comparisons to estimate the relative risk for toxic death, grade 3 to 4 (G3/4) adverse events (AEs), and discontinuation of treatment because of AE for each EGFR TKI. RESULTS: Sixteen trials included 2535 patients with mutated or wild-type EGFR. Toxic deaths were rare (1.7%), with pneumonitis being most frequent cause and no significant differences between EGFR TKIs. Overall, 40% of patients experienced G3/4 AEs. The risk for G3/4 AEs was lower with gefitinib (29.1%) than with erlotinib (54.1%) or afatinib (42.1%) (p < 0.01). Discontinuation of treatment because of AEs occurred in 7.7% of patients, with no significant differences between EGFR TKIs. Diarrhea (in 53.3% of cases) and rash (in 66.5%) were the most frequent AEs. The risk for rash was higher with afatinib (84.8%) than with erlotinib (62.0%) or gefitinib (62.0%) (p < 0.01). The risk for diarrhea was higher with afatinib (91.7%) than with erlotinib (42.4%) or gefitinib (44.4%) (p < 0.01). The risk for increased liver enzyme levels was higher with gefitinib (61.7%) than with erlotinib (17.8%) or afatinib (20.1%) (p < 0.01). A risk-benefit contour was used to assess the trade-off between efficacy and toxicity for different EGFR TKIs. CONCLUSIONS: EGFR TKIs are well tolerated, with less than 10% of patients discontinuing treatment because of AEs. The profile of and risk for toxicities vary between EGFR TKIs and can be used to inform the selection of treatment.
引用
- Ding PN, Lord SJ, Gebski V, et al. Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer. J Thorac Oncol. 2016. PMID: 28007626. doi:10.1016/j.jtho.2016.11.2236
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。